HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $35 price target.
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $35 price target.